nach oben

Drugs

Erschienen in:

01.08.2008 | Adis Drug Profile

Fentanyl Transdermal Matrix Patch (Durotep® MT Patch; Durogesic® DTrans®; Durogesic® SMAT)

In Adults with Cancer-Related Pain

verfasst von: Sheridan M. Hoy, Gillian M. Keating

Erschienen in: Drugs | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

▲ The fentanyl transdermal matrix patch is approved in Japan for the management of moderate to severe cancer-related pain in adults.
▲ Bioequivalence, in terms of exposure and the maximum and minimum serum concentrations, has been established between the fentanyl transdermal matrix patch 16.8 mg (100 μg/h) and the fentanyl transdermal reservoir patch 10 mg (100 μg/h) after single and multiple applications.
▲ The fentanyl transdermal matrix patch 2.1–8.4 mg (12.5-50 μg/h) effectively managed chronic cancer-related pain in adults in a noncomparative, multi-centre, phase II study; 89.4% of recipients rated their global assessment of pain as ‘very satisfied’, ‘satisfied’ or ‘neither satisfied nor dissatisfied’.
▲ Adults with cancer- or non-cancer-related chronic pain were switched from fentanyl transdermal reservoir patch to fentanyl transdermal matrix patch therapy without compromising efficacy; no differences in pain intensity or sleep interference scores were seen between the two formulations in an nonblind, multicentre, switching pilot study.
▲ Given the nature of the therapy, the tolerability profile of the fentanyl transdermal matrix patch was generally acceptable. Topical adverse events included erythema, application-site irritation and pruritus. In general, patients and physicians preferred the fentanyl transdermal matrix patch over the fentanyl transdermal reservoir patch in the pilot study.

The use of trade names is for product identification purposes only and does not imply endorsement.

Davis MP, Lasheen W, Gamier P. Practical guide to opioids and their complications in managing cancer pain: what oncologists need to know. Oncology (Williston Park) 2007 Sep; 21(10): 1229–38

Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15; 353(9165): 1695–700PubMedCrossRef

Schmid-Grendelmeier P, Pokorny R, Gasser UE, et al. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin 2006 Mar; 22(3): 501–9PubMedCrossRef

Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307PubMedCrossRef

Sathyan G, Guo C, Sivakumar K, et al. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005 Dec; 21(12): 1961–8PubMedCrossRef

Davis MP. Management of cancer pain: focus on new opioid analgesic formulations. Am J Cancer 2006; 5(3): 171–82CrossRef

Janssen L.P. Important drug warning [online]. Available from URL: http://www.fda.gov/medwatch/safety/2005/duragesic_ddl.pdf [Accessed 2008 Mar 10]

Durotep® MT Patch (transdermal fentanyl matrix patch) 2.1mg/4.2mg/8.4mg/12.6mg/16.8mg: Japanese prescribing information. Tokyo: Janssen Pharmaceutical K.K, 2008

Janssen-Cilag. Durogesic® DTrans® 12/25/50/75/100 trans-dermal patch: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2008 Jan 31]

10.

Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997 Jan; 53(1): 109–38PubMedCrossRef

11.

Martin WR, Eades CG, Thompson JA, et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976 Jun; 197(3): 517–32PubMed

12.

Chen Y, Mestek A, Liu J, et al. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993 Jul; 44(1): 8–12PubMed

13.

Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63(1): 17–32PubMedCrossRef

14.

Moskowitz AS, Goodman RR. Autoradiographic analysis of mul, mu2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice. Brain Res 1985 Dec 23; 360(1-2): 108–16PubMedCrossRef

15.

Suzuki T, Funada M, Narita M, et al. Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes. Brain Res 1993 Jan 29; 602(1): 45–52PubMedCrossRef

16.

Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, 2006: 547–90

17.

Sweetman SC. Martindale: the complete drug reference. 35th ed. London: Pharmaceutical Press, 2007

18.

Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 Mar 24; 213(2): 219–25PubMedCrossRef

19.

Narita M, Imai S, Itou Y, et al. Possible involvement of mul-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci 2002 Apr 5; 70(20): 2341–54PubMedCrossRef

20.

Imai S, Narita M, Itou Y, et al. Possible involvement of morphine-insensitive mul-opioid receptors in the fentanyl-induced antinociception [abstract no. Mon26]. 31st Meeting of the International Narcotics Research Conference; 2000 Jul 15–20; Seattle (WA)

21.

Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs 1995 Apr; 6 Suppl. 3: 39–43PubMedCrossRef

22.

Herz A, Albus K, Metys J, et al. On the central sites for the antinociceptive action of morphine and fentanyl. Neuropharmacology 1970 Nov; 9(6): 539–51PubMedCrossRef

23.

von Cube B, Teschemacher H, Herz A, et al. Permeation of morphine-like acting substances to their sites of antinociceptive action in the brain after intravenous and intraventricular application and dependence upon lipid-solubility [in German]. Naunyn Schmiedebergs Arch Pharmakol 1970; 265(5): 455–73CrossRef

24.

Chen SW, Maguire PA, Davies MF, et al. Evidence for mul-opioid receptor involvement in fentanyl-mediated respiratory depression. Eur J Pharmacol 1996 Sep 26; 312(2): 241–4PubMedCrossRef

25.

Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997 May; 13(5): 254–61CrossRef

26.

Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998 Jul; 81(1): 58–68PubMedCrossRef

27.

Miyazaki T, Hanaoka K, Namiki A, et al. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain. Clin Drug Invest 2008 Apr; 28(5): 313–25CrossRef

28.

Freynhagen R, von Giesen HJ, Busche P, et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005 Sep; 30(3): 289–97PubMedCrossRef

Titel: Fentanyl Transdermal Matrix Patch (Durotep® MT Patch; Durogesic® DTrans®; Durogesic® SMAT)
In Adults with Cancer-Related Pain
verfasst von: Sheridan M. Hoy
Gillian M. Keating
Publikationsdatum: 01.08.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868120-00008

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Fentanyl Transdermal Matrix Patch (Durotep® MT Patch; Durogesic® DTrans®; Durogesic® SMAT)

In Adults with Cancer-Related Pain

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2008

An Evaluation of Eptacog Alfa in Nonhaemophiliac Conditions

Mometasone Furoate

Cevimeline

Platelet Activation, and Antiplatelet Targets and Agents

Managing the Patient with Co-Morbid Depression and an Anxiety Disorder

Endothelin Receptor Antagonism